July, 2024
July 2024
Wafik S. El-Deiry: I am pleased to join Oncotarget as an Editor-in-Chief
Jul 1, 2024, 14:10

Wafik S. El-Deiry: I am pleased to join Oncotarget as an Editor-in-Chief

Wafik S. El-Deiry shared on LinkedIn:

“I am pleased to join Oncotarget as an Editor-in-Chief this June, 2024.

This is a great journal that was started in 2010. The journal has published impactful research over the years by leaders in the field.

The journal is indexed in PubMed, PMC, and MEDLINE and has its own digital archive. Oncotarget follows the guidelines based on the recommendations of the Committee on Publication Ethics (COPE).

The journal conducts author interviews and promotes published research through press releases.

I’d like to invite my colleagues to submit manuscripts and would particularly encourage translational research, progress in precision oncology, therapy for cancer’s hallmarks, drug resistance, plasticity, epigenetics, microbiome, environmental carcinogenesis, intersection of behavior and biology of cancer, cancer immunotherapy, functional precision medicine, molecular imaging, theranostics, stem cells, liquid biopsy and tumor heterogeneity.

Problems such as CNS primary or metastatic cancers, blood brain barrier research, viruses and cancer, cell cycle and cell death, biomarkers (predictive, prognostic, and pharmacodynamic), pro-drugs, nanotherapeutics, drug metabolism, novel omics, tumor dormancy and early detection are of interest.

Technology enabling of progress using AI, statistics and novel clinical trial designs, new devices for diagnostics and therapeutics, single cell profiling, 3-D visualization of TME, single molecule visualization are relevant areas of interest.

We welcome clinical case reports, case series, commentaries, reviews, clinical trial results, and Meeting Reports.

Please feel free to reach out to me directly if you have any questions or manuscripts we might consider.

I hope you will have a positive experience in sharing your contributions of new knowledge and/or expertise in an efficient manner with Oncotarget.

I look forward to having positive impact in this new role working with Mikhail Blagosklonny, (Misha) Blagosklonny and Andrei Gudkov, at Roswell Park Comprehensive Cancer Center.

I previously served as the founding Editor-in-Chief of Cancer Biology and Therapy for 18 years from 2001-2019.”

Wafik S. El-Deiry

Source: Wafik El-Deiry/LinkedIn

Wafik El-Deiry, MD, PhD, FACP, FRSM, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals.

Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. Dr. El-Deiry’s research is focused on mechanisms of therapy resistance with major efforts in drug discovery and development.